Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | DRD2 | P14416 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | HTR7 | P34969 | 1/20 | 0.85 |
| ▸ | HRH1 | P35367 | 1/20 | 0.85 |
| ▸ | DRD3 | P35462 | 1/20 | 0.85 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359039 | 0.92 | HTR1A (1.00) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL734110 | 0.90 | HTR2A (0.70) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL8872038 | 0.86 | DRD2 (0.72) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL6465788 | 0.82 | HTR2A (0.88) | HTR2AHTR1ADRD2DRD3HTR6 | |
| SCHEMBL9033157 | 0.81 | HTR2A (0.74) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL735143 | 0.80 | HTR2A (0.78) | HTR2AHTR1ADRD2DRD3HTR6 | |
| SCHEMBL30933428 | 0.80 | DHCR7 (0.60) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL14740322 | 0.80 | DHCR7 (0.60) | HTR2AHTR1ADRD2SLC6A4HTR7 | |
| SCHEMBL25295661 | 0.80 | HTR2A (1.00) | HTR2AHTR1ADRD2DRD3RAB9A | |
| SCHEMBL29543272 | 0.80 | HTR2A (0.94) | HTR2AHTR1ADRD2DRD3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280941-B1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| CN-101516844-B | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH | 2013-12-11 | — | — | CN | disclosed |
| CN-102046597-B | (hetero) arylcyclohexane derivatives | GRUENENTHAL GMBH | 2013-09-11 | — | — | CN | disclosed |
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-7977370-B2 | (Hetero)aryl cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2011-07-12 | — | — | US | disclosed |
| CN-102046597-A | (hetero) arylcyclohexane derivatives | GRUENENTHAL GMBH | 2011-05-04 | — | — | CN | disclosed |
| EP-2280941-A1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| WO-2009118163-A1 | (HETERO-)ARYL CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| EP-2044016-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009415-A2 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | Grünenthal GmbH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247573-A1 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES | OPRL1, OPRM1, OPRD1 | HTR2A 83/4885HTR1A 18/4885DRD2 215/4885 |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | HTR2A 238/4885HTR1A 746/4885DRD2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.